Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates.

Importance: Two interventions to prevent severe respiratory syncytial virus (RSV) in infants were approved in 2023-a bivalent prenatal RSV prefusion F protein-based (RSVpreF) vaccine and an infant monoclonal antibody (nirsevimab). Understanding their uptake and clinical outcomes is essential for public health planning.

Objective: To describe uptake of the prenatal RSVpreF vaccine and infant nirsevimab.

How much is enough? Exploring the dose-response relationship between cash transfers and surgical utilization in a resource-poor setting.

Objective: Cash transfers are a common intervention to incentivize salutary behavior in resource-constrained settings. Many cash transfer studies do not, however, account for the effect of the size of the cash transfer in design or analysis. A randomized, controlled trial of a cash-transfer intervention is planned to incentivize appropriate surgical utilization in Guinea.